Clinical Trials
18 trialsNCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT00049257 2020-09-01
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00005028 2019-11-04
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
University of Maryland, Baltimore
Phase 2 Completed
NCT00038246 2018-10-31
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02911350 2017-10-02
Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer
NYU Langone Health
Phase 1 Completed
NCT00003622 2017-07-13
Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
George Washington University
Phase 2 Withdrawn
NCT01558492 2017-06-09
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT00933426 2016-10-26
Lenalidomide and Paclitaxel in Prostate Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00016913 2016-07-06
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00151060 2015-01-21
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00313599 2014-07-02
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT00084565 2013-07-10
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT00003394 2013-06-24
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00005048 2012-11-09
Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NYU Langone Health
Phase 1 Completed
NCT00038168 2012-08-01
Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00003084 2012-07-30
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00667641 2011-05-10
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT00193193 2010-08-04
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed